Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate

BACKGROUND: Clinical trials have shown combinations of anti–tumor necrosis factor biologicals plus methotrexate (MTX) are more effective treatments for rheumatoid arthritis than biological monotherapies, based, in part, on the assumption that MTX reduces the immunogenicity of biologicals. However, c...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Transl Med
Autori principali: O’Mahony, Alison, John, Markus R., Cho, Hannah, Hashizume, Misato, Choy, Ernest H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5992722/
https://ncbi.nlm.nih.gov/pubmed/29879987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1532-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi